Skip to main content

Male Breast Cancer Management Study Guide

This guide explores the multifaceted approach to breast cancer treatment, including surgical interventions, radiation therapy, systemic therapies based on tumor characteristics, and the management of advanced stages of the disease. It also touches upon reconstruction and long-term survivorship care.

Save this study guide to your study set

Sign up free

Your learning path

NCCN Guidelines for Breast Cancer Management

NCCN Clinical Practice Guidelines Breast Cancer

NCCN Clinical Practice Guidelines in Oncology provide evidence and consensus regarding currently accepted approaches to treatment for breast cancer.

  • Ductal Carcinoma In Situ (DCIS)
  • Invasive Breast Cancer
  • HR-Positive Disease
  • HER2-Positive Disease
  • HR-Negative Disease
  • HER2-Negative Disease
  • Neoadjuvant Therapy
  • Adjuvant Systemic Therapy
  • Endocrine Therapy
  • Cytotoxic Therapy
  • Targeted Therapies
  • ESR1 mutation
  • PIK3CA mutation
  • Biomarker Testing
  • Trastuzumab
  • Pertuzumab
  • Aromatase inhibitor
  • CDK4/6 inhibitor

NCCN Breast Cancer Guideline Updates

Updates in Version 8.2026 of the NCCN Guidelines for Breast Cancer include revisions to locoregional treatment, systemic therapy, and surgical staging considerations.

  • Breast-Conserving Surgery (BCS)
  • Sentinel Lymph Node Biopsy (SLNB)
  • Ductal Carcinoma In Situ (DCIS)
  • Whole Breast Radiotherapy (RT)
  • Post-Mastectomy Radiotherapy (PMRT)
  • Regional Nodal Irradiation (RNI)
  • Endocrine Therapy
  • Ovarian Function Suppression (OFS)
  • Targeted Axillary Dissection (TAD)
  • Metastatic Breast Cancer
  • Oligometastatic Disease
  • HER2-positive and HER2-negative disease
  • ER-positive and ER-negative tumors
  • Gene Expression Assays
  • Breast Cancer Index (BCI)

NCCN Breast Cancer Systemic Therapy Updates

Updates to NCCN Guidelines for Breast Cancer include systemic cytotoxic therapy for recurrent unresectable or Stage IV disease and management of associated toxicities.

  • Systemic Cytotoxic Therapy
  • Recurrent Unresectable Disease
  • Stage IV Disease
  • Targeted Therapy
  • Subcutaneous Injection Substitution
  • Peripheral Neuropathy Management
  • Sacituzumab govitecan-hziy
  • Pembrolizumab
  • Datopotamab deruxtecan-dlnk
  • ILD/pneumonitis monitoring
  • ESR1 mutations
  • TMB

NCCN Breast Cancer Treatment Guidelines

NCCN Guidelines for breast cancer management including considerations for pregnancy, Ductal Carcinoma In Situ (DCIS), and surgical or systemic therapy options.

  • Breast cancer management in pregnancy
  • Ductal Carcinoma In Situ (DCIS)
  • Breast-conserving surgery (BCS)
  • Total mastectomy
  • Sentinel lymph node biopsy (SLNB)
  • Radiation therapy (RT)
  • Systemic therapy administration
  • Chemotherapy regimens
  • Endocrine therapy
  • Encapsulated papillary carcinoma (EPC)
  • Surgical axillary staging
  • Breast reconstruction
  • Estrogen receptor (ER) status

Ductal Carcinoma In Situ and Invasive Breast Cancer Management

NCCN Guidelines provide recommendations for postsurgical treatment, surveillance, and clinical staging for patients with Ductal Carcinoma In Situ and invasive breast cancer.

  • Ductal Carcinoma In Situ (DCIS) risk reduction therapy
  • Endocrine therapy for ER-positive tumors
  • Tamoxifen dosage and administration
  • Postsurgical surveillance and follow-up
  • Invasive breast cancer clinical staging
  • Surgical axillary staging and SLNB omission
  • Biomarker testing including ER/PR and HER2 status
  • Genetic counseling and testing for hereditary breast cancer
  • Locoregional treatment options including BCS and mastectomy

Invasive Breast Cancer Treatment Guidelines

Clinical recommendations for locoregional treatment and systemic adjuvant therapy based on histology, hormone-receptor status, and HER2 status.

  • Breast-conserving surgery
  • Mastectomy
  • Radiation therapy
  • Surgical axillary staging
  • Adjuvant endocrine therapy
  • Adjuvant chemotherapy
  • Hormone-receptor status
  • Pathologic nodal status
  • Gene expression assays
  • Oncoplastic reconstruction
  • Regional nodal irradiation

Systemic Adjuvant Treatment for Invasive Breast Cancer

  • Invasive breast cancer
  • HER2-positive disease
  • HER2-negative disease
  • HR-negative disease
  • Adjuvant chemotherapy
  • Trastuzumab
  • Pertuzumab
  • Adjuvant endocrine therapy
  • Bisphosphonate therapy
  • Olaparib
  • Ductal/NST
  • Lobular
  • Metaplastic carcinoma
  • Favorable histologies

Invasive Breast Cancer Management Guidelines

Clinical guidelines for invasive breast cancer including preoperative systemic therapy, surgical treatment, adjuvant therapy, and surveillance.

  • Preoperative systemic therapy
  • Breast and axillary evaluation
  • Surgical axillary staging
  • Breast conservation surgery
  • Mastectomy
  • Oncoplastic reconstruction
  • Adjuvant systemic therapy
  • Adjuvant radiation therapy
  • Regional nodal irradiation
  • Postmastectomy radiation therapy
  • Targeted Axillary Dissection
  • Sentinel lymph node biopsy
  • HER2-directed therapy
  • Endocrine therapy
  • Surveillance and follow-up

Invasive Breast Cancer Management and Survivorship

Guidelines for managing invasive breast cancer including post-treatment monitoring, endocrine therapy, and treatment of local recurrence or oligometastatic disease.

  • Post-treatment monitoring
  • Cardiotoxicity monitoring
  • Endocrine therapy adherence
  • Bone health monitoring
  • Psychosocial support
  • Oligometastatic disease management
  • Local recurrence treatment
  • Biomarker testing
  • Circulating tumor DNA assays
  • Surgical axillary staging

Management of Recurrent Invasive Breast Cancer

Multidisciplinary approach for treating locoregional recurrence and systemic treatment of recurrent unresectable or stage IV disease.

  • locoregional recurrence
  • systemic therapy
  • surgical resection
  • radiation therapy
  • axillary lymph node dissection
  • oligometastatic stage IV breast cancers
  • bone metastasis
  • ER-low–positive subgroup
  • biomarker testing
  • zoledronic acid
  • pamidronate

Systemic Treatment of Advanced Breast Cancer

Systemic therapy regimens for recurrent unresectable or stage IV disease based on ER, PR, and HER2 status.

  • Cytotoxic therapy
  • Endocrine therapy
  • Antibody-drug conjugates (ADCs)
  • Visceral crisis
  • Biomarker testing
  • ESR1 mutations
  • Ovarian ablation or suppression
  • Systemic therapy progression
  • Supportive care

Invasive Breast Cancer Management Principles

Guidelines for biomarker testing, breast MRI, fertility preservation, and axillary lymph node staging in invasive breast cancer.

  • HER2 (ERBB2) testing
  • Immunohistochemistry (IHC)
  • In situ hybridization (ISH)
  • HR testing (ER and PR)
  • Breast MRI indications
  • Fertility preservation
  • GnRH agonist therapy
  • Sentinel lymph node biopsy (SLNB)
  • Axillary lymph node dissection (ALND)

Invasive Breast Cancer Surgical Management

Guidelines regarding margin status recommendations after breast-conserving surgery and principles of breast reconstruction after surgery.

  • Breast-conserving surgery (BCS)
  • Margin status evaluation
  • Ductal carcinoma in situ (DCIS)
  • Invasive breast cancer
  • Ipsilateral breast tumor recurrence (IBTR)
  • Mastectomy indications
  • Breast reconstruction principles
  • Implant-based reconstruction
  • Autologous tissue reconstruction
  • Nipple-sparing mastectomy
  • Oncoplastic techniques
  • Radiation therapy (RT) considerations

Invasive Breast Cancer Radiation Therapy Principles

Optimizing delivery of individual radiation therapy through 3D CT-based treatment planning, target volume delineation, and dose distribution assessment for invasive breast cancer.

  • 3D CT-based treatment planning
  • Organs at risk (OAR)
  • Image-guided RT (IGRT)
  • Deep-inspiratory breath-hold (DIBH)
  • Dose-volume histograms (DVHs)
  • Hypofractionated dosing
  • Ultra-hypofractionated regimens
  • Tumor bed boost
  • Postmastectomy radiotherapy (PMRT)
  • Regional nodal irradiation (RNI)
  • Intensity-modulated RT (IMRT)
  • Volumetric modulated arc therapy (VMAT)
  • Stereotactic body RT (SBRT)

Principles of Accelerated Partial Breast Irradiation

NCCN Guidelines discuss accelerated partial breast irradiation (APBI) and partial breast irradiation (PBI) for invasive breast cancer and DCIS based on ASTRO guidelines.

  • Accelerated Partial Breast Irradiation (APBI)
  • Partial Breast Irradiation (PBI)
  • Invasive ER-positive ductal carcinoma
  • Ductal Carcinoma In Situ (DCIS)
  • Radiation therapy dose regimens
  • Interstitial brachytherapy
  • Whole breast irradiation (WBI)
  • Local control and cosmesis

Management and Special Considerations for Male Breast Cancer

Management of Breast Cancer in Males

NCCN recommendations for the management of invasive breast cancer in males include considerations for genetics, breast surgery, axillary lymph node surgery, radiation, molecular assays, and systemic therapy.

  • genetic testing
  • breast surgery
  • mastectomy
  • breast-conservation therapy
  • lymph node surgery
  • SLNB
  • radiation therapy
  • molecular assays
  • preoperative systemic therapy
  • adjuvant endocrine therapy
  • tamoxifen
  • GnRH analog
  • aromatase inhibitor
  • bone density assessment
  • systemic therapy for advanced disease
  • fulvestrant
  • CDK4/6 inhibitors
  • PARP inhibitors

Special Considerations for Male Breast Cancer

This document provides references regarding diagnosis, treatment, and survival for invasive breast cancer in males.

  • male breast cancer
  • breast-conserving therapy
  • partial mastectomy
  • sentinel lymph node biopsy
  • adjuvant radiation therapy
  • estrogen receptor-positive male breast cancer
  • aromatase inhibition
  • tamoxifen
  • fulvestrant

Systemic Therapy and Biomarkers for Invasive Breast Cancer

Invasive Breast Cancer Hormone Receptor Principles

Guidelines regarding hormone receptor-positive tumors, ER and PR testing, and endocrine therapies for invasive breast cancer.

  • Hormone receptor-positive (HR+) tumors
  • Estrogen receptor (ER) testing
  • Progesterone receptor (PR) testing
  • Endocrine therapies
  • ER-low-positive results
  • Recurrence score on gene expression assay
  • Bone mineral density (BMD) assessment
  • Aromatase inhibitor therapy
  • Tamoxifen efficacy and SSRI coadministration

Ovarian Suppression and Endocrine Therapy Guidelines

Guidelines for premenopausal patients regarding ovarian suppression, endocrine therapy, and ovarian function assessment in invasive breast cancer.

  • Ovarian suppression
  • Endocrine therapy
  • Premenopausal patients
  • Ovarian function assessment
  • Estradiol monitoring
  • Aromatase inhibitors
  • Tamoxifen
  • Disease-free survival (DFS)
  • Invasive breast cancer

Invasive Breast Cancer Systemic Therapy Guidelines

Clinical recommendations for preoperative and adjuvant systemic therapy regimens in patients with HR-positive, HR-negative, and HER2-positive invasive breast cancer.

  • adjuvant endocrine therapy
  • CDK4/6 inhibitors
  • preoperative systemic therapy
  • HR-positive/HER2-negative breast cancer
  • targeted therapy
  • ovarian suppression therapy
  • aromatase inhibitors
  • tamoxifen
  • pathologic complete response (pCR)
  • residual cancer burden (RCB)
  • neoadjuvant chemotherapy
  • trastuzumab
  • pertuzumab
  • abemaciclib
  • ribociclib
  • olaparib

Systemic Therapy Regimens for Invasive Breast Cancer

Clinical guidelines for cytotoxic regimens, endocrine therapies, and targeted agents for recurrent unresectable or stage IV invasive breast cancer based on subtype and biomarker status.

  • Germline BRCA1/2 pathogenic variants
  • PARP inhibitor (PARPi) therapy
  • Antibody-drug conjugates (ADCs)
  • PD-L1 expression and CPS scoring
  • HER2 (ERBB2) IHC and ISH testing
  • PIK3CA, AKT1, and PTEN mutations
  • ESR1 mutation detection
  • Immunotherapy-related toxicities
  • Chemotherapy-induced peripheral neuropathy management

Gene Expression Assays for Invasive Breast Cancer

Gene expression assays provide prognostic and therapy-predictive information for consideration of adjuvant systemic therapy in invasive breast cancer.

  • 21-gene assay (Oncotype Dx)
  • 70-gene signature (MammaPrint)
  • 50-gene signature (Prosigna)
  • 12-gene assay (EndoPredict)
  • Breast Cancer Index (BCI)
  • Recurrence risk
  • Adjuvant systemic therapy
  • Chemotherapy benefit prediction
  • Endocrine therapy
  • Distant recurrence risk
  • HR-positive HER2-negative tumors
  • Postmenopausal and premenopausal patient considerations

Systemic Therapy for HR-Positive Breast Cancer

Guidelines for managing invasive breast cancer through gene expression assays, menopause determination, and systemic therapy selection for hormone receptor-positive disease.

  • Gene expression assays
  • Menopause determination
  • Ovarian function assessment
  • Endocrine therapy
  • Ovarian suppression/ablation/resection
  • CDK4/6 inhibitor therapy
  • Aromatase inhibitor
  • Fulvestrant
  • Tamoxifen
  • ESR1 mutation
  • Targeted therapy

Biomarkers and FDA-Approved Therapies for Invasive Breast Cancer

This document discusses biomarkers associated with FDA-approved therapies for recurrent unresectable or stage IV invasive breast cancer.

  • Germline PALB2 mutations
  • NTRK1/2/3 gene fusion
  • Microsatellite instability-high (MSI-H)
  • Mismatch repair deficient (dMMR)
  • Tumor Mutational Burden (TMB)
  • ctDNA assays
  • Olaparib
  • Talazoparib
  • Entrectinib
  • Larotrectinib
  • Repotrectinib
  • Pembrolizumab
  • Dostarlimab-gxly
  • Selpercatinib

Invasive Breast Cancer Targeted Therapies and Regimens

Emerging biomarkers and potential targeted therapies for patients with stage IV (M1) disease including cytotoxic regimens for HER2-negative and HER2-positive breast cancer.

  • Emerging biomarkers
  • Targeted therapy
  • Somatic BRCA1/2 mutations
  • FGFR1-3 gene fusion/mutation
  • HER2-negative regimens
  • HER2-positive regimens
  • Cytotoxic regimens
  • Stage IV (M1) disease

Invasive Breast Cancer Treatment Regimens

Dosing for cytotoxic regimens and targeted therapies for recurrent unresectable or stage IV invasive breast cancer.

  • HER2-Positive Regimens
  • Cytotoxic Regimens
  • Targeted Therapies
  • Biomarker Testing
  • Vinorelbine + Trastuzumab
  • Capecitabine + Trastuzumab
  • Capecitabine/Lapatinib
  • Alpelisib/Fulvestrant
  • Capivasertib/Fulvestrant
  • Elacestrant
  • Entrectinib
  • Olaparib
  • Pembrolizumab
  • Repotrectinib
  • Selpercatinib
  • Talazoparib
  • Vepdegestrant
  • Camizestrant + CDK4/6 inhibitor

Monitoring Metastatic Breast Cancer and Phyllodes Tumor

Monitoring Principles for Metastatic Breast Cancer

Monitoring of patient symptoms and cancer burden during treatment of metastatic breast cancer includes periodic assessment of symptoms, physical examination, laboratory tests, imaging studies, and blood biomarkers.

  • Monitoring metastatic disease
  • Patient symptoms
  • Cancer burden
  • Tumor markers
  • Imaging studies
  • Bone lesions
  • Objective criteria for response/stability/progression

Breast Cancer Clinical Management and Staging

Breast Cancer Clinical Management and Staging

Guidelines for the clinical presentation, workup, and treatment of Paget disease, inflammatory breast cancer, and breast cancer during pregnancy, including AJCC TNM staging.

  • Paget disease
  • Breast cancer during pregnancy
  • Inflammatory breast cancer
  • AJCC TNM staging system
  • Primary tumor T category
  • Regional lymph nodes N category
  • Distant metastasis M category
  • Breast-conservation therapy
  • Mastectomy
  • Systemic therapy
  • Preoperative chemotherapy
  • Adjuvant endocrine therapy
  • Radiation therapy

Breast Cancer Diagnosis, Management, and Reconstruction

Breast Cancer Histologic Types and Prognostic Staging

This document details WHO classification of breast tumors and provides clinical and pathological prognostic staging based on TNM, grade, HER2, ER, and PR status.

  • Favorable Histologic Types
  • In situ carcinomas
  • Invasive Carcinomas
  • Clinical Prognostic Stage
  • Pathological Prognostic Stage
  • TNM classification
  • HER2 status
  • ER status
  • PR status
  • Oncotype DX Score
  • Genomic profile

Primary Treatment and Management of DCIS

Management strategies for DCIS include surgery, radiation therapy, and adjuvant endocrine therapy to prevent progression to invasive breast carcinoma.

  • Ductal carcinoma in situ (DCIS)
  • Breast-conserving surgery (BCS)
  • Mastectomy
  • Whole breast radiation therapy (WBRT)
  • Radiation therapy (RT) boost
  • Accelerated partial breast irradiation (APBI)
  • Tamoxifen
  • Anastrozole
  • Aromatase inhibitors
  • Sentinel lymph node biopsy (SLNB)
  • Ipsilateral breast recurrence
  • Margin status
  • Endocrine therapy
  • Estrogen receptor (ER) positive status

Non-metastatic Invasive Breast Cancer Workup

The recommended workup of localized invasive breast cancer includes history, physical examination, imaging, and pathology assessment.

  • Bilateral diagnostic mammography
  • Breast ultrasonography
  • Breast MRI indications
  • Pathology assessment
  • Biomarker determination
  • ER, PR, and HER2 status
  • CAP pathology reporting protocols
  • Genetic counseling
  • Fertility impairment

Breast Cancer Management and Fertility Preservation

Clinical considerations for breast cancer include fertility preservation options, diagnostic imaging indications, and surgical management strategies such as mastectomy or breast conserving surgery.

  • fertility preservation
  • ovarian failure
  • diagnostic imaging
  • FDG-PET/CT
  • bone scan
  • breast conserving surgery
  • mastectomy
  • risk-reducing contralateral mastectomy
  • surgical margin assessment
  • BRCA1/2 mutation

Breast Cancer Surgical and Radiation Management

Clinical guidelines for assessing surgical margins, axillary staging, and radiation therapy principles for breast cancer patients.

  • Surgical margin assessment
  • Breast conservation surgery
  • Sentinel lymph node biopsy (SLNB)
  • Axillary lymph node dissection (ALND)
  • Micrometastases
  • Targeted axillary dissection (TAD)
  • Whole breast radiation (WBRT)
  • Hypofractionated radiation schedules
  • Radiation therapy boost
  • Intensity-modulated radiation therapy (IMRT)
  • Lymphatic mapping

Breast Cancer Radiation Therapy Recommendations

NCCN Panel recommendations for whole breast radiation, accelerated partial breast irradiation, regional nodal irradiation, and post-mastectomy radiation therapy.

  • Whole breast radiation (WBRT)
  • Hypofractionated radiation therapy
  • Accelerated partial breast irradiation (APBI)
  • Regional nodal irradiation (RNI)
  • Chest wall radiation
  • Post-mastectomy radiation therapy (PMRT)
  • Tumor bed boost
  • Internal mammary nodal irradiation
  • Adjuvant radiation therapy after breast-conserving surgery (BCS)
  • Radiation therapy after mastectomy
  • Preoperative systemic therapy and radiation sequencing
  • Radiation dose fractionation

Breast Reconstruction Options and Considerations

Breast reconstruction may be an option for patients receiving surgical treatment for breast cancer using implants or autogenous tissues.

  • Breast reconstruction options
  • Implant reconstruction
  • Subpectoral expander implant
  • Autogenous tissue methods
  • Pedicle flap
  • Free flaps
  • Latissimus dorsi flap
  • Gluteus maximus myocutaneous flap
  • Reconstruction complications
  • Symmetry and contralateral breast surgery

Breast Cancer Reconstruction and Mastectomy Techniques

This document discusses breast reconstruction methods, skin-sparing mastectomy procedures, and oncoplastic techniques for breast conservation.

  • immediate breast reconstruction
  • delayed breast reconstruction
  • autogenous tissue reconstruction
  • composite reconstruction
  • implant reconstruction
  • capsular contracture
  • post-mastectomy radiation
  • skin-sparing mastectomy
  • NAC-sparing mastectomy
  • oncoplastic volume displacement
  • mastopexy techniques
  • breast-conserving lumpectomy

Preoperative and Adjuvant Systemic Therapies

Guidelines regarding preoperative systemic therapy and adjuvant systemic therapy for breast cancer patients based on tumor biology and hormone receptor status.

  • Preoperative systemic therapy
  • Adjuvant systemic therapy
  • Breast conservation
  • Pathologic complete response (pCR)
  • Residual Cancer Burden (RCB)
  • Hormone receptor (HR) status
  • HER2-positive breast cancer
  • Triple-negative breast cancer (TNBC)
  • Endocrine therapy
  • Tamoxifen
  • Aromatase inhibitors
  • Ovarian function suppression (OFS)
  • Neoadjuvant therapy
  • Oncoplastic procedures

Adjuvant and Advanced Breast Cancer Management

Adjuvant Therapy for Breast Cancer

  • Adjuvant bisphosphonate therapy
  • Dose-dense chemotherapy schedules
  • Adjuvant capecitabine for TNBC
  • Olaparib for germline BRCA 1/2 mutations
  • Trastuzumab and pertuzumab combinations
  • Neratinib for HR-positive tumors
  • Post-therapy surveillance and follow-up
  • Bone health monitoring in endocrine therapy
  • Cardiac toxicity and LVEF assessment

Management of Recurrent and Stage IV Breast Cancer

Clinical guidelines for the staging, workup, and management of patients with recurrent or stage IV breast cancer including systemic therapy and local management.

  • Staging and workup for recurrent/stage IV breast cancer
  • Management of locally recurrent disease
  • Systemic therapy for metastatic disease
  • Bone-modifying agents for metastatic bone disease
  • Treatment of visceral crisis and extensive visceral metastases
  • CDK4/6 inhibitors in combination with endocrine therapy
  • Germline BRCA1/2 mutation assessment

Breast Cancer Therapeutic Management and Clinical Research

Treatment Options for HR-Positive Breast Cancer

Clinical trial data and NCCN recommendations for CDK4/6 inhibitors, endocrine therapy, and PI3K pathway inhibitors in advanced breast cancer management.

  • CDK4/6 inhibitors
  • ribociclib
  • abemaciclib
  • palbociclib
  • endocrine therapy
  • aromatase inhibitors
  • fulvestrant
  • inavolisib
  • alpelisib
  • capivasertib
  • PIK3CA mutations
  • progression-free survival
  • overall survival
  • HR-positive HER2-negative breast cancer
  • adverse events

Endocrine and Targeted Therapies for Breast Cancer

Clinical trial data evaluates the efficacy and safety of capivasertib, everolimus, elacestrant, imlunestrant, and vepdegestrant in patients with HR-positive breast cancer and specific genetic alterations.

  • PI3K pathway alterations
  • mTOR signal transduction pathway
  • ESR1 activating mutations
  • capivasertib
  • elacestrant
  • imlunestrant
  • vepdegestrant
  • progression-free survival (PFS)
  • overall survival (OS)
  • aromatase inhibitors (AIs)
  • selective estrogen receptor modulators (SERMs)
  • fulvestrant
  • CDK4/6 inhibitors

Therapy for HR-Positive and HER2-Positive Breast Cancer

Treatment regimens for metastatic breast cancer including endocrine therapy-targeted therapy.

  • HER2-ultralow breast cancer
  • Fulvestrant dosing regimens
  • Abemaciclib single-agent activity
  • PARP inhibitors for germline BRCA1/2 pathogenic variants
  • Trastuzumab efficacy and adverse events
  • Sacituzumab govitecan in second-line settings
  • Datopotamab deruxtecan-dlnk clinical trial results
  • Pertuzumab, trastuzumab, and taxane (THP) combinations
  • Tucatinib and capecitabine for CNS progression
  • Interstitial lung disease and pneumonitis monitoring

Therapeutic Options for Metastatic Breast Cancer

Treatment regimens for HER2-positive, HR-positive, and triple-negative breast cancer including targeted therapies, endocrine therapy, and cytotoxic chemotherapy.

  • trastuzumab
  • lapatinib
  • margetuximab-cmkb
  • HR-positive HER2-positive breast cancer
  • endocrine therapy
  • aromatase inhibitors
  • CDK4/6 inhibitors
  • maintenance therapy
  • triple negative breast cancer (TNBC)
  • sacituzumab govitecan-hziy
  • datopotamab deruxtecan-dlnk
  • germline BRCA1/2 pathogenic variants
  • PARP inhibitors
  • platinum agents
  • NTRK gene fusion
  • MSI-H/dMMR solid tumors
  • HER2 (ERBB2) activating mutations
  • FGFR1-4 alterations

Monitoring and Special Breast Cancer Situations

Clinical management involves monitoring metastatic disease, Paget disease, phyllodes tumors, and breast cancer during pregnancy.

  • Monitoring metastatic breast cancer
  • Circulating tumor cells (CTC)
  • Circulating tumor DNA (ctDNA)
  • Paget disease of the breast
  • Breast-conserving surgery (BCS)
  • Total mastectomy
  • Phyllodes tumors
  • Breast cancer during pregnancy

Management of Pregnancy and Inflammatory Breast Cancer

Clinical evaluation, staging, and systemic therapy recommendations for pregnant patients with breast cancer and the treatment protocols for inflammatory breast cancer.

  • Breast cancer in pregnancy
  • Mammogram with shielding
  • Core needle biopsy
  • Fetal malformation risks
  • Systemic chemotherapy in pregnancy
  • Trastuzumab use during pregnancy
  • Inflammatory breast cancer (IBC) diagnosis
  • Dermal lymphatic involvement
  • Preoperative systemic therapy
  • Anthracycline-based chemotherapy
  • Taxane addition
  • HER2-positive IBC treatment
  • Mastectomy and axillary lymph node dissection
  • Radiotherapy for IBC

Management of Axillary and Occult Breast Cancer

Clinical guidance for the diagnosis and treatment of patients presenting with axillary metastases or suspected occult primary breast cancer.

  • axillary breast cancer
  • occult primary breast cancer
  • core needle biopsy
  • fine needle aspiration
  • breast MRI
  • mammography
  • breast ultrasound
  • immunohistochemical markers
  • ER/PR
  • HER2
  • mastectomy
  • whole breast irradiation
  • ductal carcinoma in situ
  • lumpectomy
  • systemic chemotherapy
  • endocrine therapy
  • trastuzumab

Breast Cancer Treatment and Management References

This document provides a comprehensive list of clinical references regarding hormone receptor status, metastatic breast cancer management, and various therapeutic interventions.

  • hormone receptor status
  • HER-2 expression
  • metastatic breast cancer
  • locoregional recurrence
  • bisphosphonates
  • CDK4/6 inhibitors
  • aromatase inhibitors
  • endocrine therapy
  • PIK3CA mutations
  • ESR1 mutations

Breast Cancer Treatment and Clinical Research

This document provides a bibliography of clinical studies regarding neoadjuvant chemotherapy, endocrine therapy, and surgical approaches for breast cancer.

  • neoadjuvant chemotherapy
  • neoadjuvant endocrine therapy
  • adjuvant tamoxifen
  • anastrozole
  • letrozole
  • exemestane
  • oncoplastic surgery
  • skin-sparing mastectomy
  • triple-negative breast cancer
  • HER2-positive breast cancer
  • estrogen receptor-positive breast cancer
  • pathologic complete response
  • residual cancer burden
  • hormone receptor-positive breast cancer

Breast Cancer Endocrine Therapy and Pharmacogenetics

This document provides a bibliography of clinical trials and studies regarding adjuvant endocrine therapy, aromatase inhibitors, tamoxifen, and pharmacogenetics in breast cancer management.

  • adjuvant endocrine therapy
  • tamoxifen
  • aromatase inhibitors
  • exemestane
  • letrozole
  • anastrozole
  • ovarian suppression
  • premenopausal breast cancer
  • postmenopausal breast cancer
  • pharmacogenetics
  • 21-gene recurrence score assay
  • hormone receptor-positive breast cancer

Breast Cancer Adjuvant Therapy Clinical Evidence

A compilation of clinical trial data and research studies regarding adjuvant treatment options for breast cancer patients.

  • 21-gene recurrence score assay
  • 70-gene signature
  • PAM50 risk of recurrence score
  • Breast Cancer Index (BCI) assay
  • Adjuvant endocrine therapy
  • Trastuzumab and pertuzumab dual blockade
  • Adjuvant chemotherapy regimens
  • Zoledronic acid and denosumab in breast cancer
  • BRCA1 and BRCA2 mutation status
  • Neoadjuvant chemotherapy
  • Distant recurrence prediction

Breast Cancer Clinical Trial References

This document provides a comprehensive list of clinical trial citations and research studies regarding various treatments for advanced, metastatic, and HER2-positive breast cancer.

  • advanced breast cancer
  • metastatic breast cancer
  • hormone receptor-positive breast cancer
  • HER2-positive breast cancer
  • endocrine therapy
  • trastuzumab emtansine
  • pertuzumab
  • lapatinib
  • anastrozole
  • fulvestrant
  • aromatase inhibitor
  • sacituzumab govitecan
  • margetuximab
  • capecitabine
  • palbociclib
  • abemaciclib

Breast Cancer Clinical Research References

A collection of medical literature references regarding Paget disease, phyllodes tumors, breast cancer during pregnancy, inflammatory breast cancer, and occult breast carcinoma.

  • Paget disease of the breast
  • Phyllodes tumors
  • Breast cancer during pregnancy
  • Inflammatory breast cancer
  • Occult breast carcinoma
  • Sentinel lymph node biopsy
  • Neoadjuvant chemotherapy
  • Trastuzumab use in pregnancy
  • HER-2 status
  • Magnetic resonance imaging in breast cancer

Make it your own.

Keep these readings and topics in a new study set, or add them to one you already use.

Get started freeLog in